Phase 2 Oesophageal Cancer Trial, Recruiting NCT06906887 Sponsor: Medical College of Wisconsin Condition: Oesophageal Cancer
Back to Oesophageal Cancer

Phase 2 Oesophageal Cancer Trial, Recruiting

NCT06906887
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Adults aged 18 or older
  • People diagnosed with Stage II to IVb adenocarcinoma (a type of cancer) of the esophagus — if Stage IVb, only those with a small number of spread sites (called oligometastatic), where the treating doctor considers a full-dose chemotherapy and radiation treatment plan to be appropriate
  • People who are currently receiving or have already received an initial course of chemotherapy, and who are planned to receive a full course of combined chemotherapy and radiation treatment (with or without surgery to remove the esophagus)
  • People whose general health and ability to carry out daily activities falls within an acceptable range, as measured by a standard medical scale (ECOG score of 0–2) (confirm with trial site)
  • People whose blood cell counts fall within required levels, based on a blood test taken within the past 30 days: enough white blood cells, red blood cells, and platelets to safely participate
  • People whose kidneys are functioning well enough, based on a blood test within the past 30 days
  • People whose liver is functioning well enough, based on a blood test within the past 30 days — those with a condition called Gilbert Syndrome may have a slightly different acceptable range (confirm with trial site)
  • Women under 65 who could become pregnant must have a negative pregnancy test within 14 days before joining the trial
  • People who are able to use effective birth control throughout the treatment period, if there is a possibility of pregnancy
  • People who have had or currently have another type of cancer, as long as that cancer or its treatment is not expected to affect the safety or results of this trial
  • People who are able to understand the written consent form and are willing to sign it

Who may not be able to join:

  • People under 18 years of age
  • People whose cancer has spread widely to more than 5 distant sites in the body
  • People whose esophageal cancer has come back after previous treatment (recurrent cancer)
  • People who have previously received chemotherapy that has not been formally approved for cancer treatment
  • People who have previously had radiation therapy to the same area of the body being treated in this trial, if the radiation fields would overlap
  • Women who are currently pregnant or breastfeeding

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 21 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Lindsay Puckett, MD, Medical College of Wisconsin

Phone: 866-680-0505

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Medical College of Wisconsin
Registry
ClinicalTrials.gov
Start date
17 June 2025
Est. completion
1 November 2030

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

New prescription for narcotics; Increasing existing narcotics; Oral intake

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov